Health Alert – Investigation of Toxic Anterior Segment Syndrome and Request for Cases

Regarding:

KEY POINTS:

– CDPHE is investigating a cluster of Toxic Anterior Segment Syndrome (TASS) among patients following cataract surgeries. All three patients identified received the same type and lot number of ophthalmic viscosurgical device (OVD). The investigation is ongoing.

– CDPHE recommends that health care providers and ophthalmologic suppliers check their supplies of OVDs for Amvisc Plus lot number D130087A, manufactured by Bausch & Lomb. This specific lot number should not be used on patients until more information is available.

– CDPHE requests that any cases of TASS diagnosed between January 1, 2015 – present where Amvisc Plus, (manufactured by Bausch & Lomb) was used, or cases of TASS where the type of OVD is unknown, be reported to the Communicable Disease Branch by contacting Devra Barter at 303-692-2706 or devra.barter@state.co.us.

For further information:

For questions or additional information, please contact Devra Barter (303-692-2706 or devra.barter@state.co.us) in the Communicable Disease Branch at CDPHE.